指南与共识重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症患者β-内酰胺类抗生素治疗优化:法国药理学与治疗学学会(SFPT)和法国麻醉与重症医学学会(SFAR)指南

Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR).
指南 / 共识 · Crit Care · 2019-03-29
一句话结论SFPT-SFAR指南强烈建议重症患者使用β-内酰胺类抗生素时采用个体化给药、持续或延长输注及治疗药物监测。

该指南由法国药理学与治疗学学会(SFPT)和法国麻醉与重症医学学会(SFAR)联合制定,18名专家组成的共识委员会基于PICO问题、PRISMA文献检索(2000年1月以来)和GRADE方法学,因缺乏以死亡率为主要终点的有力研究,仅制定「可选」推荐。最终就21条可选推荐和涵盖四个领域(药代动力学变异性、PK-PD关系、给药方式、治疗药物监测)的总结性照护算法达成强烈共识。最重要的推荐包括:考虑ICU患者多种PK变异来源;将游离血药浓度维持在致病菌最低抑菌浓度(MIC)的4至8倍、覆盖100%给药间隔作为PK-PD目标;对最严重患者、高MIC细菌及下呼吸道感染使用持续或延长输注以改善临床治愈;使用TDM以提高PK-PD目标达成率。

要点

  • β-内酰胺类PK-PD目标:游离血药浓度维持在致病菌MIC的4至8倍,覆盖100%给药间隔,以最大化细菌学和临床应答。
  • 对最严重患者、高MIC细菌及下呼吸道感染,推荐使用β-内酰胺类持续或延长输注以改善临床治愈。
  • 推荐使用治疗药物监测(TDM)以提高PK-PD目标达成率。
  • ICU患者存在多种药代动力学变异来源,处方β-内酰胺类时应考虑个体化给药。
  • 因缺乏以死亡率为主要终点的有力研究,本指南仅制定21条「可选」推荐。

适用人群与场景

  • 重症监护病房(ICU)患者,接受β-内酰胺类抗生素治疗。

诊断标准与关键阈值

  • PK-PD目标:游离血药浓度维持在致病菌最低抑菌浓度(MIC)的4至8倍,覆盖100%的给药间隔。

处置流程与药物剂量

  • 考虑ICU患者中多种药代动力学变异来源,进行个体化给药。
  • 对最严重患者、高MIC细菌及下呼吸道感染,使用β-内酰胺类持续或延长输注以改善临床治愈。
  • 使用治疗药物监测(TDM)以提高PK-PD目标达成率。

研究设计与关键结果

  • 由SFPT和SFAR组成的18名专家共识委员会制定,过程独立于任何产业资助,采用PICO模型提出问题,两位文献专家按PRISMA建议分析2000年1月以来文献,采用GRADE®方法学评估证据质量。
  • 因缺乏以死亡率为主要终点的有力研究,在起草推荐前决定仅制定「可选」推荐。
  • 经过两轮评级和一次修订,SFPT-SFAR指南小组就21条可选推荐和涵盖四个领域的总结性照护算法达成强烈共识:药代动力学变异性、PK-PD关系、给药方式、治疗药物监测。

证据类型、等级与局限

  • 证据类型:指南(共识指南)。
  • 推荐强度:所有推荐均为「可选」推荐;专家对21条可选推荐达成强烈共识。
  • 局限:因缺乏以死亡率为主要终点的有力研究,仅制定「可选」推荐。

对床旁实践的改变

  • 专家强烈建议在重症患者使用β-内酰胺类抗生素时采用个体化给药、持续或延长输注以及治疗药物监测。
  • 对最严重患者、高MIC细菌及下呼吸道感染,推荐使用持续或延长输注以改善临床治愈。
  • 推荐使用TDM以提高PK-PD目标(游离浓度4至8倍MIC覆盖100%给药间隔)的达成率。

指南或共识出处

  • 指南名称:重症患者β-内酰胺类抗生素治疗优化指南;发布机构:法国药理学与治疗学学会(SFPT)和法国麻醉与重症医学学会(SFAR)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Beta-lactam antibiotics (βLA) are the most commonly used antibiotics in the intensive care unit (ICU). ICU patients present many pathophysiological features that cause pharmacokinetic (PK) and pharmacodynamic (PD) specificities, leading to the risk of underdosage. The French Society of Pharmacology and Therapeutics (SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (SFAR) have joined forces to provide guidelines on the optimization of beta-lactam treatment in ICU patients.

METHODS: A consensus committee of 18 experts from the two societies had the mission of producing these guidelines. The entire process was conducted independently of any industry funding. A list of questions formulated according to the PICO model (Population, Intervention, Comparison, and Outcomes) was drawn-up by the experts. Then, two bibliographic experts analysed the literature published since January 2000 using predefined keywords according to PRISMA recommendations. The quality of the data identified from the literature was assessed using the GRADE® methodology. Due to the lack of powerful studies having used mortality as main judgement criteria, it was decided, before drafting the recommendations, to formulate only "optional" recommendations.

RESULTS: After two rounds of rating and one amendment, a strong agreement was reached by the SFPT-SFAR guideline panel for 21 optional recommendations and a recapitulative algorithm for care covering four areas: (i) pharmacokinetic variability, (ii) PK-PD relationship, (iii) administration modalities, and (iv) therapeutic drug monitoring (TDM). The most important recommendations regarding βLA administration in ICU patients concerned (i) the consideration of the many sources of PK variability in this population; (ii) the definition of free plasma concentration between four and eight times the Minimal Inhibitory Concentration (MIC) of the causative bacteria for 100% of the dosing interval as PK-PD target to maximize bacteriological and clinical responses; (iii) the use of continuous or prolonged administration of βLA in the most severe patients, in case of high MIC bacteria and in case of lower respiratory tract infection to improve clinical cure; and (iv) the use of TDM to improve PK-PD target achievement.

CONCLUSIONS: The experts strongly suggest the use of personalized dosing, continuous or prolonged infusion and therapeutic drug monitoring when administering βLA in critically ill patients.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). Crit Care. 2019. PMID: 30925922. doi:10.1186/s13054-019-2378-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。